Le Loupp Anne-Gaelle, Bach-Ngohou Kalyane, Bourreille Arnaud, Boudin Hélène, Rolli-Derkinderen Malvyne, Denis Marc G, Neunlist Michel, Masson Damien
INSERM Unité 913, 1 rue Gaston Veil, Nantes, F-44035, France.
Université Nantes, 1 quai de Tourville, BP 13522, Nantes, F-44035, France.
BMC Gastroenterol. 2015 Sep 4;15:112. doi: 10.1186/s12876-015-0338-7.
Recent works provide evidence of the importance of the prostaglandin D2 (PGD2) metabolic pathway in inflammatory bowel diseases. We investigated the expression of PGD2 metabolic pathway actors in Crohn's disease (CD) and the ability of the enteric nervous system (ENS) to produce PGD2 in inflammatory conditions.
Expression of key actors involved in the PGD2 metabolic pathway and its receptors was analyzed using quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) in colonic mucosal biopsies of patients from three groups: controls, quiescent and active CD patients. To determine the ability of the ENS to secrete PGD2 in proinflammatory conditions, Lipocalin-type prostaglandin D synthase (L-PGDS) expression by neurons and glial cells was analyzed by immunostaining. PGD2 levels were determined in a medium of primary culture of ENS and neuro-glial coculture model treated by lipopolysaccharide (LPS).
In patients with active CD, inflamed colonic mucosa showed significantly higher COX2 and L-PGDS mRNA expression, and significantly higher PGD2 levels than healthy colonic mucosa. On the contrary, peroxysome proliferator-activated receptor Gamma (PPARG) expression was reduced in inflamed colonic mucosa of CD patients with active disease. Immunostaining showed that L-PGDS was expressed in the neurons of human myenteric and submucosal plexi. A rat ENS primary culture model confirmed this expression. PGD2 levels were significantly increased on primary culture of ENS treated with LPS. This production was abolished by AT-56, a specific competitive L-PGDS inhibitor. The neuro-glial coculture model revealed that each component of the ENS, ECG and neurons, could contribute to PGD2 production.
Our results highlight the activation of the PGD2 metabolic pathway in Crohn's disease. This study supports the hypothesis that in Crohn's disease, enteric neurons and glial cells form a functional unit reacting to inflammation by producing PGD2.
近期研究表明前列腺素D2(PGD2)代谢途径在炎症性肠病中具有重要作用。我们研究了PGD2代谢途径相关因子在克罗恩病(CD)中的表达情况,以及肠神经系统(ENS)在炎症状态下产生PGD2的能力。
采用定量逆转录聚合酶链反应(qRT-PCR)分析三组患者结肠黏膜活检组织中参与PGD2代谢途径的关键因子及其受体的表达,这三组患者分别为:对照组、静止期CD患者和活动期CD患者。为确定ENS在促炎条件下分泌PGD2的能力,通过免疫染色分析神经元和神经胶质细胞中脂质运载蛋白型前列腺素D合成酶(L-PGDS)的表达。在脂多糖(LPS)处理的ENS原代培养物和神经-胶质共培养模型的培养基中测定PGD2水平。
活动期CD患者的炎症性结肠黏膜中,COX2和L-PGDS mRNA表达显著高于健康结肠黏膜,PGD2水平也显著更高。相反,活动期CD患者炎症性结肠黏膜中过氧化物酶体增殖物激活受体γ(PPARG)的表达降低。免疫染色显示L-PGDS在人肌间神经丛和黏膜下神经丛的神经元中表达。大鼠ENS原代培养模型证实了这一表达。LPS处理的ENS原代培养物中PGD2水平显著升高。这种产生被特异性竞争性L-PGDS抑制剂AT-56消除。神经-胶质共培养模型显示,ENS的每个组成部分,即肠神经胶质细胞(ECG)和神经元,都可能参与PGD2的产生。
我们的结果突出了PGD2代谢途径在克罗恩病中的激活。本研究支持以下假设:在克罗恩病中,肠神经元和神经胶质细胞形成一个功能单元,通过产生PGD2对炎症作出反应。